Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
84 hedge funds and large institutions have $216M invested in Unity Biotechnology in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 11 closing their positions.
25,500% more call options, than puts
Call options by funds: $256K | Put options by funds: $1K
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
70% more capital invested
Capital invested by funds: $127M → $216M (+$89.3M)
14% more funds holding
Funds holding: 74 → 84 (+10)
0.47% more ownership
Funds ownership: 4.6% → 5.07% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.07M |
| 2 |
Millennium Management
New York
|
+$3.72M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.58M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.33M |
| 5 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$481K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$413K |
| 3 |
Cerity Partners
New York
|
-$348K |
| 4 |
VEA
Virtus ETF Advisers
New York
|
-$249K |
| 5 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
-$226K |
UBX Hedge Fund Activity: Q2 2020 in Review
84 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2020, worth a combined $216M — up 70% from $127M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new UBX positions and 11 closed out — a net gain of 10 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $5.07M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $481K.
- 84 institutional investors held Unity Biotechnology (UBX) as of Q2 2020, up from 74 in Q1 2020.
- Funds reported $216M of Unity Biotechnology stock for Q2 2020, up 70% quarter-over-quarter.
- 21 funds opened new Unity Biotechnology positions in Q2 2020 and 11 closed out, a net change of +10 holders.
- The largest Unity Biotechnology buyer in Q2 2020 was BlackRock, an estimated $5.07M added.
- The largest Unity Biotechnology seller in Q2 2020 was Jacobs Levy Equity Management, an estimated $481K sold.
Based on aggregated 13F filings for Q2 2020.